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Abstract. Recent studies indicate that small amyloid- peptide (A) oligomers are the major toxic species responsible for
development and progression of Alzheimer’s disease (AD). Therefore, we suggest that the number of A oligomers in body
fluids is the most direct and relevant biomarker for AD. Determination of the A oligomer content of cerebrospinal fluid (CSF)
samples from 14 AD patients and 12 age-matched controls revealed a clear distinction between both groups. All samples of the
control group showed homogenously low numbers of A oligomers, while the samples of the AD group exhibited significantly
higher levels of A oligomers. The A oligomer numbers correlated with the patients’ Mini-Mental State Examination scores.
This indicates that the quantity of A oligomers in CSF reflects the severity of the disease and that A oligomers play a crucial
role in AD pathology and in turn can be used as a diagnostic biomarker.
Keywords: Alzheimer disease, amyloid- peptide, early diagnosis, sFIDA, surface based fluorescence intensity distribution
analysis
INTRODUCTION
Alzheimer’s disease (AD) is a fatal neurodegener-
ative and progressive disorder and the most common
form of dementia, which will become a threat to our
health care systems, if prevention and treatment efforts
continue to fail. The sensitivity and specificity for
clinical diagnosis of AD is 70 to 90% in specialized
centers, but considerably lower for patients with
early AD or in primary care settings [1–3]. Early
diagnosis will aid treatment decisions substantially,
as the majority of scientists currently agrees that AD
treatment will be most effective in preclinical stages
of the disease [4]. Therefore, a reliable biomarker and
a reliable method for its quantification are urgently
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needed to allow trial inclusion of humans at very early,
pre-symptomatic stages of the disease. Reducing the
level of the very same biomarker and the delayed or
avoided appearance of clinical symptoms could then
be clearly defined treatment objectives.
Aggregation of neurotoxic amyloid- (A) is
believed to play a major role in the development of
AD. A is derived from the amyloid- protein pre-
cursor (APP) by sequential activities of the - and
-secretases [5–7], and is the major component of
amyloid plaques. The most abundant A species con-
sist of 38 to 43 amino acid residues of which A42
and especially pyro-glutamated species are prone to
aggregation and undergo formation from monomers to
oligomers, protofibrils, insoluble fibrils, and plaques
[8, 9]. As originally suggested by the amyloid cascade
hypothesis [10, 11], A aggregates initiate cellular
events leading to the pathologic effects of AD. Recent
studies support that, in particular, the small diffusible
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A oligomers are the major toxic species respon-
sible for disease development and progression [12].
Although the monomeric form of A is not the main
responsible isoform for neurotoxicity and neurodegen-
eration, a variety of studies have demonstrated that
reduced levels of A1-42 monomers in CSF, as deter-
mined by ELISA or related methods, implicate a high
predictive value for the identification of prodromal AD
even in cases of mild cognitive impairment (MCI). Evi-
dence was found that combined biochemical analysis
of tau and phosphorylated tau in CSF, both of which
are increased in CSF of AD patients in comparison to
controls, and detection of A levels can improve the
diagnostic value predicting AD with sensitivity and
specificity values of 80 to 95% [13, 14]. However,
because of substantial readout overlap between indi-
viduals of different groups, no definite diagnosis for all
individual patients is currently possible. Regardless of
the potential role of hyperphosphorylated tau protein
and its aggregates, aggregation of A is regarded as a
very early event in the disease. Thus, the appearance of
A aggregates in body fluids, especially in CSF, may
be one of the earliest events to be detectable during
disease development and progression, and the ability
to quantify them could not only enhance AD diagnosis,
but also aid in the investigation of the contribution of
A aggregates to AD pathology. The quantification of
A aggregates in CSF basically requires the solution
of two major technical problems: first, full discrimi-
nation between A monomers and A aggregates is
needed, and second, maximum sensitivity is desired,
preferably at the single aggregate level.
Starting in 2005, a number of reports have been
published describing techniques for the measurement
of A aggregate contents in body fluids. Many of
them are based on ELISA, but to date, only a few
methods were suggested that have the potential for
single A aggregate detection sensitivity in body flu-
ids [15, 16]. In 2006, Birkmann et al. reported on the
detection of single prion protein particles by fluores-
cence correlation spectroscopy (FCS) in solution after
labeling them by two different fluorescence-labeled
anti-prion protein antibodies [17]. In 2007, the method
was refined by including an immobilization step for
the aggregates to a glass surface using prion protein-
specific capture antibodies, and subsequent detection
of the fluorescent probe decorated prion protein aggre-
gates by the laser focus of a FCS device while it
was moved across the glass surface. This procedure
allowed counting fluorescence events originating from
each prion protein particle in CSF of bovine spongi-
form encephalopathy (BSE) infected cattle. The assay
was denominated Surface-FIDA (surface fluorescence
intensity distribution analysis) or sFIDA [18]. Applica-
tion of sFIDA even allowed the distinction of Scrapie
infected sheep from healthy sheep by quantifying prion
protein particles in blood plasma samples [19]. In
recent years, it was shown that sFIDA is principally
applicable to count A aggregates in human CSF
samples. In addition, it was possible to replace the
FCS device by a laser scanning microscope (LSM)
[20–22].
Based on the sFIDA principle, we optimized the
assay into an ultrasensitive A aggregate detection
system using anti-A-antibodies as capture and detec-
tion probes. We describe the experimental features of
the redesigned sFIDA assay and report on the results
that we obtained from a challenge of the assay with
26 human CSF samples that were obtained from AD-
affected subjects and age-matched non-AD controls.
MATERIALS AND METHODS
Materials
All chemicals were purchased from Sigma-Aldrich
(Munich, Germany) with analytical grade or chem-
ically pure unless noted otherwise. Ultrapure water
(Milli-Q, water resistivity = 18.2 M·cm, Millipore
GmbH, Schwalbach/Ts., Germany) was used in all
experiments.
Preparation of synthetic Aβ monomers and
oligomers using size exclusion chromatography
(SEC)
Lyophilized, synthetic A42 peptide was purchased
(JPT Technologies, Berlin, Germany). To dissolve
pre-existing aggregation seeds, the A peptide was dis-
solved in 1,1,1,3,3,3- hexafluoro-2-propanol (HFIP) to
a concentration of 400M and incubated overnight at
room temperature. After HFIP was evaporated, Awas
dissolved in running buffer (50 mM sodium phosphate,
150 mM NaCl, pH 7.4 with 0.6% Tween-20) to a final
concentration of 500M. The sample was centrifuged
for 5 min at 16,100× g. 100l of supernatant were
loaded onto a SEC column (Superdex 75 10/300 GL,
GE Healthcare, Uppsala, Sweden). The samples were
eluted at room temperature, at a flow rate of 0.5 ml/min,
with running buffer and detected at 214 nm, according
to the protocol of Johansson et al. [23]. The concen-
trations of A oligomer and monomer fractions were
determined using the Micro BCATM Protein Assay
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Kit (Thermo Scientific, Rockford, USA) following the
instructions of the manufacturer. The A-containing
fractions were incubated for 30 min in 3 M Urea at
60◦C to disassemble A oligomers. The solutions were
mixed with micro BCA reagents and incubated further
for 30 min at 60◦C. Each sample was tested in duplicate
in a 96-well microplate (Greiner Bio-one, Fricken-
hausen, Germany) and the peptides were detected with
a wavelength of 570 nm in a plate reader POLARstar
OPTIMA (BMG Labtech, Offenburg, Germany). For
A species detection using sFIDA, A monomers and
oligomers were further diluted in PBS to the desired
concentrations.
Fluorescence labeling of antibodies
6E10-Alexa-Fluor 488 was purchased (Covance,
Dedham, MA, USA). For labeling of Nab228
(Sigma-Aldrich, Munich, Germany), the fluorescence
monoclonal antibody labeling kit Alexa-Fluor 647
(Molecular Probes, Karlsruhe, Germany) was used
according to the manufacturer’s instructions. The puri-
fied fluorescence-labeled antibodies were stored in
PBS and 2 mM sodium azide, at 4◦C in the dark.
Design of the sFIDA assay
Glass surface preparation and covalent
immobilization of Aβ capture antibodies
384-Well SenoPlateTM Plus microplates (Greiner
bio-one, Frickenhausen, Germany, borosilicate glass
bottom with a well surface of 10 mm2) were used
to perform sFIDA. Because the polystyrene frame is
chemically not inert, a gentle protocol was applied
to activate the glass surface for subsequent amina-
tion using ethanolamine, partly according to Janissen
et al. [24]. After cleaning the glass surface with
cleaner solution in an ultrasonic bath, the surface
was incubated with 5 M NaOH for 3 h, rinsed with
water and ethanol and dried afterwards. The glass
was subsequently immersed in DMSO containing
5 M ethanolamine overnight [25], followed by wash-
ing three times with DMSO and three times with
ultrapure water. For the reduction of unspecific
fluorescent background caused by the binding of flu-
orescent probes or sample material to the surface,
glass-shielding carboxymethyldextran (CMD) was
immobilized to the glass surface activated with amino
groups. CMD was dissolved in water to a concentration
of 10 mg/ml and mixed with 200 mM N-Ethyl-
N′-(3-dimethylaminopropyl)carbodiimide (EDC) and
50 mM N-Hydroxysuccinimide (NHS). After 10 min
pre-incubation the solution was incubated on the amino
group activated glass surface for 2 h at room tempera-
ture, leading to covalent linking of CMD to the glass
surface via ester bonds. Finally the glass surface was
rinsed with water.
A second activation step with EDC/NHS (5 min,
200/50 mM, respectively) was applied to the plates
prepared as described above. The capture antibodies
(Nab228) were added and incubated for 2 h at 4◦C for
their covalent immobilization on the CMD activated
glass surface of the microtiter plate wells. To deacti-
vate remaining carboxylate end groups of the CMD
spacer, 1 M ethanolamine in DMSO was applied for
15 min. The wells were rinsed with PBS three times
before the samples were added.
Sample application to sFIDA and data evaluation
Samples were either synthetic A monomers or
oligomers in PBS, or human CSF. None of the sam-
ples was blinded prior to analysis. Samples were added
to the capture antibody coupled glass microtiterplate
wells and incubated for 1 h to immobilize A present
in the sample at the bottom of the glass well. The wells
were rinsed twice with TBST (0.1% (w/w) Tween-
20, 50 mM Tris-HCl; 0.15 M NaCl, pH 7.4). Next,
fluorescence-labeled A detection antibodies 6E10-
Alexa-Fluor 488 and Nab228-Alexa-Fluor 647 were
added. After 1 h incubation at room temperature and
consecutive washing steps, the measurements were
performed on a laser scanning microscope LSM710
(Carl Zeiss, Jena, Germany). The microscope was
equipped with an argon ion laser (ex = 488 nm) and a
helium-neon laser (ex = 633 nm).
The glass surface was scanned by the argon
(ex = 488 nm) and helium-neon laser (ex = 633 nm).
In total, 50 images (213m×213m per image) con-
taining 1024×1024 pixels were scanned for each
sample in the tile scan mode, 25 images per tile scan.
The area for each tile scan was randomly chosen, but
the edges of the well were avoided. The totally scanned
area covered about 20% of each well.
The image data were analyzed using the
open source image processing software ImageJ
(http://rsbweb.nih.gov/ij/). The images obtained from
channel 1 (6E10-Alexa-Fluor 488) and channel 2
(Nab228-Alexa-Fluor 647) were merged and the
number of crosscorrelated pixels that were above the
threshold value in both channels was counted for
every of the 50 images per sample. Intensity cut-off
values of two for the green channel and 1 for the red
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Table 1
Summary of sample specifications
Specification Subject ID No. Age Gender MMSE sFIDA readout
Control 7090076 69 M 30 10387
Control 7090084 72 M 30 22474
Control 7807 74 F 30 5016
Control 7808 66 M 29 4494
Control 7827 73 F 28 8124
Control 7828 70 M 30 11814
Control 7830 80 F 30 6169
Control 7837 73 F 30 24413
Control 7840 76 F 29 10898
Control 7844 75 M 30 8682
Control 7846 70 M 30 8255
Control 7852 81 F 30 7530
Mean value 73 30 6169
AD 308 93 M 2 22524
AD 312 86 F 24 445840
AD 322 94 F 9 350160
AD 8001 83 M 15 329032
AD 8005 80 M 14 450637
AD 8026 78 F 15 308302
AD 8029 74 M 14 274639
AD 8040 87 M 19 161557
AD 8057 77 F 15 152676
AD 8058 72 F 11 149527
AD 8060 79 M 17 150300
AD 8061 82 F 16 170509
AD 8077 77 F 15 139320
AD 8106 71 F 15 138045
Mean value 83 15 231647.71
p-value of sFIDA readout means between AD and control groups <0.001
MMSE, Mini–Mental State Examination score.
channel excluded background with low fluorescence
intensities from the analysis.
Human CSF samples
CSF samples of elderly controls and subjects diag-
nosed with AD were purchased from PrecisionMed,
Inc. (San Diego, CA) and stored at −80◦C until use.
The sample specifications can be seen in Table 1.
RESULTS
Design of the sFIDA assay
Starting from the basic principle of the “sFIDA”
assay [17, 18], which has been developed to detect
and quantify prion protein aggregates from scrapie-
infected hamster as well as BSE-infected cattle, and
an earlier version of this assay adapted to detect A
aggregates [20, 21], we optimized the assay to an even
more sensitive and highly specific A oligomer detec-
tion and quantification assay. The details are described
in the methods section and a general scheme of the
procedure is shown in Fig. 1. Differences between the
earlier sFIDA version and the assay described here are
summarized in Table 2.
Briefly, in order to avoid unspecific binding of A
aggregates to the glass surface of microtiter plate wells,
we covalently covered the glass surface with CMD. An
anti-A-antibody (Nab228) was covalently linked to
the CMD treated surface as a capture for A species
eventually contained in the samples. After application
of the sample and thorough washing, fluorescence-
labeled anti-A-antibodies (6E10-Alexa-Fluor-488
and Nab228-Alexa-Fluor-647) were applied to deco-
rate potentially present A oligomers in the sample.
The use of capture and detection antibodies with
overlapping epitopes avoided fluorescence-labeling of
capture-bound Amonomers. After final washing, the
presence of fluorescent probes on the surface indicated
the presence of A oligomers. The use of two differ-
ent anti-A-antibodies, each one labeled with another
fluorescent dye, further increased the specificity
of the detection procedure using LSM by count-
ing only fluorescence events that show fluorescence
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Fig. 1. Scheme of the sFIDA assay. A aggregates or oligomers are
captured and concentrated onto a two-dimensional surface by immo-
bilizing them on a glass surface (grey bottom plane) with covalently
linked A capture antibodies (dark grey Y-letters). A aggre-
gates (brownish pale bundles) are detected by adding at least two
fluorescence-labeled anti-A antibodies (light grey Y-letters). Laser
beams with wavelengths suitable for excitation of the employed flu-
orescent dyes are focused on the surface of the glass chip and the
fluorescence light which is emitted by the fluorescence-labeled anti-
bodies is detected, allowing single aggregate detection sensitivity.
Either a fluorescence correlation spectroscopy (FCS) device or a
laser scanning microscope (LSM) can be used.
intensities above background thresholds in both emis-
sion channels.
Validation of sFIDA with synthetic Aβ oligomers
We tested the newly designed sFIDA with known
amounts of synthetic A oligomers prepared by SEC.
SEC purified A monomer samples with the same
total A content and samples without any A were
used as negative controls. Various amounts of A
monomers and oligomers in PBS buffer were applied
to the sFIDA assay. Images from the A oligomer
containing samples as well as of the control sam-
ples (Fig. 2A–C) showed that the A oligomers were
spread homogenously on the surface. In both negative
controls, virtually no fluorescence was detectable. The
sFIDA readout is shown in Fig. 2D. Application of
A oligomers resulted in considerably high signals,
whereas the readout for A monomers was as low as
for the control without any A. To evaluate the linear-
ity of the assay, A oligomers were diluted serially in
PBS and applied to the assay. The correlation between
A concentration and readout was linear over a wide
range of A amounts, even down to the low picogram
range (Fig. 2E).
Application of human CSF samples from AD
patients and age-matched controls to sFIDA
To challenge the sFIDA assay with real samples,
we applied CSF samples in 12.5l volume from AD
patients and age-matched non-demented controls. The
exact specifications of the samples as well as the
respective sFIDA readouts are shown in Table 1. As
can be seen in Fig. 3, the mean value of the sFIDA
readout of the AD group was significantly higher than
that of the age-matched control group, allowing a clear
and highly significant distinction between both groups.
The AD group showed high variations among samples,
whereas the control group showed homogenously low
levels of A aggregate count. All but one AD sam-
ples resulted in significantly elevated sFIDA readouts
as compared to the control samples. For the small num-
ber of samples tested, this yields a sensitivity of 93%
and a specificity of 100%.
Interestingly, the sFIDA readout correlated with the
Mini-Mental State Examination (MMSE) scores of
the CSF donors (Fig. 4). We found a significant neg-
ative correlation with the MMSE scores (r2 = 0.35;
p = 0.0016). Thus, the sFIDA readout seems to reflect
the severity of the disease. The correlation between
sFIDA readout and age of the patients was less clear
(p = 0.0116, r2 = 0.2373), but a trend toward more
oligomers with age could be observed, which might
be affected by the fact that the AD patients were on
average 10 years older (mean 83, range 71 to 94) than
the controls (mean 73, range 76–84).
Table 2
Summary of specifications for the earlier and novel sFIDA version
Specification Version 2007 [20] Recent version
Capture antibody immobilization Unspecific adsorption, poly-D-lysine Covalent, carboxymethyldextran
Background fluorescence Comparably high due to unspecific binding of fluorescent
probes and sample proteins to glass surface
Significantly reduced
Principle of detection Fluorescence correlation spectroscopy Laser scanning microscopy
Data output Fluorescence intensities over time Images, Pixel
Sensitivity as judged by detection of
synthetic A oligomers
nM scale pM scale
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Fig. 2. sFIDA is insensitive to Amonomers. A oligomers and monomers were prepared using size exclusion chromatography (SEC) according
to the protocol of Johansson et al. [23]. The A species were immobilized on the CMD glass surface via capture antibody Nab228. As detection
antibodies Nab228-Alexa-Fluor 647 and 6E10-Alexa-Fluor 488 were applied. PBS without A was used as control. LSM images of 0.2M A
oligomers (A), 0.2M monomers (B), and PBS control without A (C). The sFIDA readouts of all these samples are given in D. The standard
deviation was calculated from six tile scan measurements. The sensitivity of the assay was determined by dilution of the oligomers in PBS
buffer (E).
DISCUSSION
A oligomer formation and toxicity is reported to be
a key event in AD progression [12, 26]. The develop-
ment of techniques for the specific detection of A
oligomers is technically challenging. A oligomers
may be present in CSF only in trace amounts [27]
and are highly diverse in respect of size and struc-
ture. A variety of different oligomer conformers,
ranging from dimers to 56 mers and higher order
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Fig. 3. Results of sFIDA from AD and control CSF samples. Of
each CSF sample, 12.5l were directly applied to capture antibody
covered wells. In total, 50 images (213m × 213m per image) of
1024 × 1024 pixels were recorded for each sample. The total number
of crosscorrelated pixels above a threshold of one for the red channel
and a threshold of two for the green channel was calculated for each
of the 50 images, and the mean value is given for each sample. Error
bars indicate the standard error of the mean (SEM). The significance
was calculated using unpaired student’s T-test. The horizontal bars
represent the mean value of all data points within one group, the
corresponding SEM is indicated. ***p < 0.001.
oligomers, have been described in vitro and in vivo
[8, 12, 26, 28–32]. The expected low abundance of
oligomers demands for methods with intrinsically high
sensitivity.
We hereby present an updated sFIDA assay with
improvements to render it fully applicable as a tool to
quantify A oligomers with single particle sensitivity
in human CSF samples (also see Table 2). Compared
to other assays and principles, sFIDA has some major
advantages. i) The assay is completely insensitive to
A monomers. ii) It does not require any pretreatment
of the CSF samples and thus avoids artificial changes
in the aggregation state of A species contained in the
samples. iii) By using conformation-unspecific anti-
A antibodies, the assay is not restricted to certain
A aggregate species. In the present study, we used
anti-A antibodies that are directed against linear epi-
topes located at the amino-terminal end of A, which
seems to be exposed in all A aggregate conformers
[33]. If desired, it is straightforward to use confor-
mation specific capture and/or detection antibodies
to allow for example quantification of certain sub-
species of A oligomers. iv) Although not shown in
the present work, it may be straightforward to corre-
late the detected fluorescence signal intensities with
the sizes of the respective aggregates, because the
larger the aggregates, the more epitopes are present, the
more detection antibodies will bind. This is a property
clearly superior to sandwich ELISA protocols, which
Fig. 4. A) Correlation between sFIDA readout and MMSE scores
(p = 0.0016; r2 = 0.35). Each point represents a single case. The best-
fit linear regression is shown by a solid line and the 95% confidence
interval by interrupted lines. B) Correlation between sFIDA read-
out and age of the patients, independent of diagnosis. (p = 0.0116,
r2 = 0.2373). Each point represents a single case. The best-fit linear
regression is shown by a solid line and the 95% confidence interval
by interrupted lines.
cannot differentiate a large number of small oligomers
from a small number of large aggregates. (v) The most
important advantage of sFIDA in comparison to ELISA
approaches is its sensitivity. Each CSF sample applied
to an ELISA yields exactly one readout value. Thus,
the presence of only a few oligomers will possibly not
lead to a readout value clearly above background. Each
CSF sample applied to sFIDA, however, yields mil-
lions of readout values, dependent on the pixel size
and the number of the images taken. Each image pixel
is able to generate one readout value for each observed
emission channel. We have developed several options
to combine this wealth of information into one or
more readout values per well. In the current mode of
the sFIDA data evaluation, we counted the number of
pixels that show fluorescence intensities above back-
ground in both emission channels that were used for
detection. This number may correlate with the number
of A aggregate particles. (vi) The principle of sFIDA
can easily be adapted to any other protein aggregates
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to be detected. (vii) It is straightforward to include
more detection probes with additional fluorescence
colors in order to obtain even higher specificity and/or
more information on the detected aggregates. (viii)
We used a LSM for data collection. Other methods
like total internal reflection fluorescence microscopy
are working comparatively well (data not shown). If
desired, the data evaluation may be carried out with
any super-resolution imaging method, e.g., stimulated
emission depletion or stochastic optical reconstruc-
tion microscopy [34], in order to yield highly resolved
information about size and shape of the aggregates.
We challenged the assay with 26 human CSF sam-
ples that were obtained from AD-affected subjects and
age-matched non-AD controls. Only 12.5l of each
sample were sufficient and adequate to investigate the
A oligomer readout of each sample. The A oligomer
count allowed a clear distinction between both groups.
All but one AD samples resulted in a clearly increased
sFIDA readout compared to the control samples. We do
not want to over-stress this singular result, but interest-
ingly the one CSF sample of the AD group with very
low sFIDA readout was obtained from a donor with
an MMSE of only 2. Possibly the brain of this donor
was already damaged to an extent that interfered with
the production of A. Another potential explanation
is more general: if the current gold standard of AD
diagnosis has a specificity of 90%, then any diagnos-
tic tool with 100% specificity needs to disagree with
the current gold standard in 10% of the cases. Thus,
the outlayer of the AD CSF sample group may have
been misdiagnosed and might have been affected by
any other form of dementia. Unfortunately, a follow-up
study of this CSF donor was not possible.
Our study emphasizes the usefulness of A
oligomers or higher molecular weight aggregates as a
biomarker for AD. Together with other reports on vari-
ous approaches to quantify A aggregates, we also find
that the amount of A aggregates was higher in CSF
samples from AD patients as compared to CSF sam-
ples from non-demented controls [16, 20, 27, 35–40].
Similar to our study, Fukomoto et al. [36] also found
a correlation between the amount of A aggregates in
CSF and the MMSE score of the respective donors.
These results further strengthen the view that the num-
ber of A oligomers may reflect disease severity and
progress. The finding that the concentration of A
oligomers is increased in CSF of AD patients in com-
parison to healthy controls seems to contradict ELISA
studies revealing that the total or monomer A amount
decreases with disease progression [41–44]. Englund
et al., however, found evidence that the lowering of
monomeric A42 might be caused by its oligomer-
ization and deposition in plaques [35]. Indeed, the
decrease of A42 concentration in CSF is strongly and
inversely correlated with A deposition in the brain, as
measured by amyloid imaging studies using positron
emission tomography [45]. Thus, the reported decrease
of monomeric A might well be in accordance with
the observed increase of aggregated A with disease
progression.
In summary, our results demonstrate that A
oligomers as quantified by sFIDA have a high poten-
tial to be used as a biomarker to clearly discriminate
CSF from AD patients and healthy age-matched con-
trols. The correlation between sFIDA readout from the
CSF samples and the MMSE score of the respective
patients supports the role of A aggregates for disease
development and progression. Thus, A aggregate
quantification by sFIDA may allow early diagnosis of
pre-symptomatic AD cases. This in turn may render the
assay as a useful tool to include pre-symptomatic cases
into clinical trials for therapy development. The A
oligomer count may become useful for therapy moni-
toring and its reduction may even become a potential
therapy objective. Currently, a variety of compounds
for treatment of AD are developed [46], and reliable
biomarkers will be necessary to prove that the drug of
interest has disease modifying effects and changes the
pathophysiology of the disease [41].
For potential use of sFIDA detected A oligomers
as biomarker in clinics, robustness of the method will
have to be proven in longitudinal studies of large
cohorts. Although lumbar puncture is moderately inva-
sive and has low incidence of complications [47], the
detection of A oligomers in blood plasma would be
of great value for wider diagnostic use and for ther-
apy monitoring. Consequently, sFIDA may become a
method for reliable detection and quantitation of A
oligomers in any biological sample (e.g., CSF, blood,
organs) in order to investigate their role in AD pathol-
ogy and progression. It may be sensitive enough to
follow the “prion-like” propagation of A aggregates
in vitro and in vivo to assess the role of “prion-like”
A aggregates for transmission of the disease from
one animal to another.
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